Jupiter Neurosciences, Inc. (JUNS)
Jupiter Neurosciences, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Jupiter Neurosciences, Inc. (JUNS) is a Biotechnology company based in US with a market capitalization of $6.2M. Free cash flow was negative at -$5.4M. This page tracks JUNS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 4 employees · IPO Jan 18, 2022
Valuation
Valuation & price
$0.34as of May 17, 2026· -81.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$6.2M
Market cap
—
Revenue growth (YoY)
80.6%
Gross margin
-$5.4M
Free cash flow (USD)
$1.5M
Net debt
20.3%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 14, 2026 (EPS $-0.06)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 21, 2026Filing
Strategic Asset License Agreement
- 8-K eventJun 30, 2026Filing
Director Appointment
- 8-K eventJun 22, 2026Filing
Director Resignation
- 8-K eventJun 5, 2026Filing
Executive Appointment
- 8-K eventMay 21, 2026Filing
Securities Purchase Agreement
- 8-K eventMay 20, 2026Filing
Licensing Agreement Proposed
- Quarterly reportMay 14, 2026Filing
10-Q Filed
- FinancingApr 16, 2026Filing
Securities Registration
- Annual reportApr 1, 2026Filing
10-K Filed
Questions
Frequently asked questions
What is Jupiter Neurosciences, Inc.'s market cap?
Jupiter Neurosciences, Inc. (JUNS) has a market capitalization of $6.2M.
What is JUNS's P/E ratio?
A meaningful P/E ratio is not available for JUNS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
When did Jupiter Neurosciences, Inc. last report earnings?
JUNS last reported earnings on May 14, 2026; the next date is not yet scheduled.
Are insiders buying JUNS stock?
SEC Form 4 filings show no open-market insider buys at Jupiter Neurosciences, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.